%0 Journal Article
%A Mitzlaff, Katharina
%A Kirstein, Martha M
%A Müller, Christian
%A Venerito, Marino
%A Olkus, Alexander
%A Dill, Michael T
%A Weinmann, Arndt
%A Kocheise, Lorenz
%A Busch, Alina
%A Schulze, Kornelius
%A Allo, Gabriel
%A Waldschmidt, Dirk-Thomas
%A Barsch, Maryam
%A Bengsch, Bertram
%A Quante, Michael
%A Gonzalez-Carmona, Maria A
%A Himmelsbach, Vera
%A Finkelmeier, Fabian
%A Kloeckner, Roman
%A Schirmacher, Peter
%A Marquardt, Jens U
%A Zimpel, Carolin
%T Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
%J United european gastroenterology journal
%V 12
%N 9
%@ 2050-6406
%C Hoboken, NJ
%I Wiley
%M DKFZ-2024-01905
%P 1230-1242
%D 2024
%Z 2024 Nov;12(9):1230-1242
%X Combined Immuno-chemotherapy consisting of gemcitabine, cisplatin and the programmed death-ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on positive results of the TOPAZ-1 study.We here evaluated the efficacy and safety of GCD for BTC in a German multicenter real-world patient cohort.Patients with BTC treated with GCD from 9 German centers were included. Clinicopathological baseline parameters, overall survival (OS), response rate and adverse events (AEs) were retrospectively analyzed. The prognostic impact was determined by Kaplan-Meier analyses and Cox regression models.A total of 165 patients treated with GCD between 2021 and 2024 were included in the study. Median OS and median progression-free survival were 14 months (95
%K biliary tract cancers (Other)
%K check‐point inhibition (Other)
%K cholangiocarcinoma (Other)
%K cisplatin (Other)
%K durvalumab (Other)
%K gemcitabine (Other)
%K immuno‐chemotherapy (Other)
%K programmed death‐ligand 1 inhibitor (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39301763
%R 10.1002/ueg2.12656
%U https://inrepo02.dkfz.de/record/293582